Williams Christopher I, Mahmoudinobar Farbod, Thompson David C, Davis J Wade, Kumar Sandeep
Chemical Computing Group, 1010 Sherbrooke Street West, Montreal, Quebec H3A 2R7, Canada.
Molecule Design and Modeling Group, Computational Science, Research and Early Development, Moderna Therapeutics, 325 Binney Street, Cambridge, Massachusetts 02142, United States.
Mol Pharm. 2025 Aug 4;22(8):4679-4692. doi: 10.1021/acs.molpharmaceut.5c00250. Epub 2025 Jul 22.
Antibody-based biotherapeutics make up an important class of biopharmaceuticals. However, their discovery requires resource- and time-consuming laboratory processes. To ameliorate this situation, several computational methods were used to predict the structures of antibody:antigen complexes (Ab:Ag) and identify potential binders, in-silico. However, there is still a general lack of rapid virtual screening methods capable of screening large antibody libraries against a given antigen or group of antigens. In this work, we explore the application of a successful small-molecule drug discovery strategy and adapt pharmacophore-based virtual screening to the world of antibody discovery. Using a nonredundant data set of 874 Ab:Ag complexes, we have developed an automated method to create pharmacophores from the antibody complementarity determining regions. Our method is 98.6% (862 out of 874) successful at reproducing the ground truth, i.e., it can recapitulate the parental antibody:antigen complexes. In a benchmarking comparison with cognate docking, using 33 Ab:Ag complexes of , the pharmacophore method was not only much faster than cognate docking but also recovered all the native interfacial contacts. In addition, it can also find additional putative antibody binders to a given antigen within clusters of Ab:Ag complexes with similar interfacial structures. Our method has significant implications toward accelerating biotherapeutic drug discovery as well as drug repurposing research. This method was implemented in MOE 2024 and is available to the scientific community.
基于抗体的生物疗法是一类重要的生物制药。然而,其发现需要耗费资源和时间的实验室流程。为改善这种情况,人们使用了几种计算方法来预测抗体-抗原复合物(Ab:Ag)的结构并在计算机上识别潜在的结合物。然而,仍然普遍缺乏能够针对给定抗原或一组抗原筛选大型抗体库的快速虚拟筛选方法。在这项工作中,我们探索了一种成功的小分子药物发现策略的应用,并将基于药效团的虚拟筛选应用于抗体发现领域。使用包含874个Ab:Ag复合物的非冗余数据集,我们开发了一种从抗体互补决定区创建药效团的自动化方法。我们的方法在重现真实情况方面成功率为98.6%(874个中的862个),即它可以概括亲本抗体-抗原复合物。在与同源对接的基准比较中,使用33个Ab:Ag复合物,药效团方法不仅比同源对接快得多,而且还恢复了所有天然界面接触。此外,它还可以在具有相似界面结构的Ab:Ag复合物簇中找到针对给定抗原的其他推定抗体结合物。我们的方法对加速生物治疗药物发现以及药物再利用研究具有重要意义。该方法已在MOE 2024中实现,并可供科学界使用。